Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Sajid Khan(The University of Texas at San Antonio Health Science Center), Daohong Zhou(The University of Texas at San Antonio Health Science Center)
Cited by 43
Related Papers
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
|Nature Communications|2021|145
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
|Journal of Hematology & Oncology|2020|129